Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vered Abitbol

Showing results (71-80 of 83) with videos related to

Pageof 9
Sort By:
Journal of Crohn'S & Colitis|July 13, 2016
Negative Screening Does Not Rule Out the Risk of Tuberculosis in Patients with Inflammatory Bowel Disease Undergoing Anti-TNF Treatment: A Descriptive Study on the GETAID CohortYael Abitbol, David Laharie, Jacques Cosnes, et al.
Gastroenterology|December 4, 2015
Methotrexate Is Not Superior to Placebo for Inducing Steroid-Free Remission, but Induces Steroid-Free Clinical Remission in a Larger Proportion of Patients With Ulcerative ColitisFranck Carbonnel, Jean Frédéric Colombel, Jérome Filippi, et al.
Gastroenterology|April 19, 2026
CLONAL LYMPHOCYTE EXPANSIONS AND JAK-STAT PATHWAY MUTATIONS DEFINE A PATHOGENIC CONTINUUM DRIVING RESISTANCE TO GLUTEN-FREE DIET IN CELIAC DISEASEGeorgia Malamut, Nicolas Guégan, Francesco Carbone, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|May 10, 2024
Long-term Outcome of Risankizumab in Crohn's Disease: a Real-world GETAID StudyMathurin Fumery, Benedicte Caron, Xavier Hébuterne, et al.
Journal of Crohn'S & Colitis|March 29, 2023
Prevalence and Determinants of Fatigue in Patients with IBD: A Cross-Sectional Survey from the GETAIDAurelien Amiot, Sayma Chaibi, Yoram Bouhnik, et al.
Journal of Crohn'S & Colitis|November 27, 2020
The IBD-disk Is a Reliable Tool to Assess the Daily-life Burden of Patients with Inflammatory Bowel DiseaseSara Tadbiri, Maria Nachury, Yoram Bouhnik, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|November 6, 2024
Risk of Incident Cancer in Patients with Inflammatory Bowel Disease with Prior Breast Cancer: A Multicenter Cohort StudyGuillaume Le Cosquer, Julien Kirchgesner, Cyrielle Gilletta De Saint Joseph, et al.
United European Gastroenterology Journal|March 25, 2026
Efficacy and Safety of Second-Line Advanced Therapy After Vedolizumab in Ulcerative Colitis: A Multicenter Cohort Study From the GETAIDLouis Calméjane, Catherine Reenaers, Claire Gay, et al.
Journal of Crohn'S & Colitis|April 25, 2025
Endoscopic submucosal dissection for visible dysplasia in inflammatory bowel disease: a nationwide multicenter cohort from the GETAID and the SFEDSophie Geyl, Jérémie Jacques, Alicia Anneraud, et al.
Rheumatology (Oxford, England)|August 24, 2021
IgA vasculitis in patients with inflammatory bowel disease: new insights into the role of TNF-α blockersCamille Rasmussen, Vered Abitbol, Khalil El Karoui, et al.
Pageof 9

Showing results (71-80 of 83) with videos related to

Sort By:
Pageof 9
Journal of Crohn'S & Colitis|July 13, 2016
Negative Screening Does Not Rule Out the Risk of Tuberculosis in Patients with Inflammatory Bowel Disease Undergoing Anti-TNF Treatment: A Descriptive Study on the GETAID CohortYael Abitbol, David Laharie, Jacques Cosnes, et al.
Gastroenterology|December 4, 2015
Methotrexate Is Not Superior to Placebo for Inducing Steroid-Free Remission, but Induces Steroid-Free Clinical Remission in a Larger Proportion of Patients With Ulcerative ColitisFranck Carbonnel, Jean Frédéric Colombel, Jérome Filippi, et al.
Gastroenterology|April 19, 2026
CLONAL LYMPHOCYTE EXPANSIONS AND JAK-STAT PATHWAY MUTATIONS DEFINE A PATHOGENIC CONTINUUM DRIVING RESISTANCE TO GLUTEN-FREE DIET IN CELIAC DISEASEGeorgia Malamut, Nicolas Guégan, Francesco Carbone, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|May 10, 2024
Long-term Outcome of Risankizumab in Crohn's Disease: a Real-world GETAID StudyMathurin Fumery, Benedicte Caron, Xavier Hébuterne, et al.
Journal of Crohn'S & Colitis|March 29, 2023
Prevalence and Determinants of Fatigue in Patients with IBD: A Cross-Sectional Survey from the GETAIDAurelien Amiot, Sayma Chaibi, Yoram Bouhnik, et al.
Journal of Crohn'S & Colitis|November 27, 2020
The IBD-disk Is a Reliable Tool to Assess the Daily-life Burden of Patients with Inflammatory Bowel DiseaseSara Tadbiri, Maria Nachury, Yoram Bouhnik, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|November 6, 2024
Risk of Incident Cancer in Patients with Inflammatory Bowel Disease with Prior Breast Cancer: A Multicenter Cohort StudyGuillaume Le Cosquer, Julien Kirchgesner, Cyrielle Gilletta De Saint Joseph, et al.
United European Gastroenterology Journal|March 25, 2026
Efficacy and Safety of Second-Line Advanced Therapy After Vedolizumab in Ulcerative Colitis: A Multicenter Cohort Study From the GETAIDLouis Calméjane, Catherine Reenaers, Claire Gay, et al.
Journal of Crohn'S & Colitis|April 25, 2025
Endoscopic submucosal dissection for visible dysplasia in inflammatory bowel disease: a nationwide multicenter cohort from the GETAID and the SFEDSophie Geyl, Jérémie Jacques, Alicia Anneraud, et al.
Rheumatology (Oxford, England)|August 24, 2021
IgA vasculitis in patients with inflammatory bowel disease: new insights into the role of TNF-α blockersCamille Rasmussen, Vered Abitbol, Khalil El Karoui, et al.
Pageof 9